BRIEF-Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease

* GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.